Novartis Ag

Sunesis Pharmaceuticals, Inc.

Millennium Pharmaceuticals Limited

Biogen Idec Ma Inc.

Robert Lowell Simmons

Folkert Reck

Anthony Casarez

Xiaodong Lin

Qingming Zhu

Mika Lindvall

Heinz Ernst Moser

Kevin Guckian

Matthew T Burger

Wen-Cherng Lee

Edward Yin-Shiang Lin

Lei Zhang

Lihong Sun

Daniel A Erlanson

Aregahegn Yifru

Benjamin R Taft

Gisele A Nishiguchi

Meiliana Tjandra

Thinh Nguyen

Alice C Rico

Stig Hansen

Glenn McEnroe

Huw Roland Tanner

Guido Koch

Virender Singh Aulakh

Kathy Jingyuan Cao

Markus Furegati

Joseph E Drumm, Iii

Nuzhat Pathan

Kenneth Egnard Lind

Flavio Ossola

Bradley T Tangonan

Michael Mutz

Zaixing Li

Andreas Fisch

Bernd Ulrich Riebesehl

Vijay Sethuraman

Eric Aubin

Marc Schoenhentz

Joseph Drumm Iii

Glenn Mcenroe

Gisele Nishiguchi

The invention provides new solid forms, salts and polymorphs of 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (referred to herein as Compound X), pharmaceutical compositions containing them, and processes for their manufacture and use in therapy.

Salts and solid forms of a monobactam antibiotic

This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains. 

Beta-lactamase inhibitors

This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.

Monobactam organic compounds for the treatment of bacterial infections

This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains.

The present invention provides pyridinonyl PDK1 inhibitors and methods of treating cancer using the same.

Methods of treatment using pyridinonyl PDK1 inhibitors

The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.

Ring-substituted N-pyridinyl amides as kinase inhibitors

Pyridinonyl PDK1 inhibitors

Growing community of inventors

San Francisco, CA, United States of America

Robert Lowell Simmons